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Abstract 
We present a rare case of small cell carcinoma of the rectum presenting with rectal 
bleeding and discomfort in a fit 51-year-old gentleman. Our patient was treated with a 
combination of chemotherapy and radiotherapy and remains alive and free of disease 6 
years after diagnosis. Our patient experience and review of the literature is presented 
highlighting the uncertainties regarding the biological behaviour and management. 
 
Introduction 
Small cell carcinomas (SCC) are malignancies deriving from neuroendocrine tissue 
and although the gastrointestinal tract contains the largest population of neuroendocrine 
cells, these malignancies are rare. Through amine precursor uptake and decarboxylation 
system, neuroendocrine cells are capable of synthetizing, storing and secreting a variety of 
neuroamines, neuropeptides and related substances [1]. 
Small cell neoplasia most commonly originates in the lung but also other sites such as 
skin, thymus, kidney, breast, ovary, uterus, urinary bladder, hepatobiliary tree, pancreas, 
and salivary glands [2] (extrapulmonary small cell carcinoma, EPSCC). More specifically, 
the colorectal SCC accounts for 0.2% [3] to 1.5% [4] of all colonic cancers and is 
considered to be an aggressive neoplasm with rapid growth and early spread carrying 
poor prognosis [3]. The chemosensitivity of the EPSCC is reported to be similar to small 
cell lung cancer (SCLC) with similar chemotherapeutic agents. Case Rep Oncol 2011;4:475–480 
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Case Report 
A 51-year-old fit gentleman presented with a short history of pelvic discomfort, perianal pain and 
bleeding per rectum. The patient was non-smoker and the only comorbidity was hypertension-induced 
cardiomegaly. Per-rectal examination confirmed a large obstructing tumour in the lower rectum. 
Imaging (CT chest/abdomen/pelvis; fig. 1) confirmed a large rectal mass extending from the anorectal 
junction to the mid rectum with multiple enlarged perirectal and mesorectal lymph nodes. 
The rectal biopsy demonstrated a poorly differentiated malignant tumour with surface ulceration 
(fig. 2). Immunohistochemistry revealed that tumour cells were negative for cytokeratin, LCA 
(lymphoid marker) and S100 but positive for CD56 (neural cell adhesion molecule, NCAM) and 
chromogranin, consistent with a diagnosis of small cell (neuroendocrine) carcinoma (fig. 3). Staging CT 
scan and bone scan excluded any metastatic spread beyond the pelvis. 
The case was discussed in the colorectal multidisciplinary meeting and was felt to be inoperable at 
the time and the recommendation was to treat with a combination of chemotherapy and radiotherapy. 
The patient was commenced on chemotherapy (August 2005) consisting of alternate cycles of 
cyclophosphamide 800 mg/m
2 day 1 + liposomal doxorubicin 50 mg/m
2 day 1 + vincristine 1.4 mg/m
2 
day 1 (CAV) and carboplatin AUC 5 day 1 (600 mg) + etoposide 100 mg/m
2 i.v. day 1, day 2 and day 3 
(EP) repeated every 3 weeks for 6 cycles. Liposomal doxorubicin was chosen as the patient had 
preexisting hypertension-induced cardiomegaly. The patient tolerated chemotherapy well and his 
symptoms improved drastically following chemotherapy. 
Following completion of chemotherapy, the patient received consolidation radiotherapy to the pelvis 
to a dose of 30 Gy/10#. A restaging CT scan of chest/abdomen/pelvis in January 2006 demonstrated 
good partial response with minimal residual rectal disease (thickening) and no distant metastasis. 
Maintenance chemotherapy was offered with weekly i.v. etoposide (100 mg/m
2) 3 weeks on and 1 week 
off for further 6 cycles. 
A repeat CT at this stage confirmed unchanged appearance of rectal wall thickening and no new 
findings (fig. 4). This resulted in the patient receiving further 6 cycles of carboplatin and etoposide 
repeated at 4 weekly intervals. Subsequent CT scan (December 2006) again revealed unchanged 
appearance of rectal wall, which on sigmoidoscopy appeared normal. One year after completion of 
treatment, a CT/PET scan (December 2007) confirmed no residual active disease in the pelvis or 
elsewhere. Last CT scan from June 2009 confirmed no evidence of recurrence and the patient remains 
well and free of disease on clinical examination 4.5 years after completion of treatment (6 years after 
diagnosis). 
Discussion 
EPSCC – initially described by Duguid and Kennedy in 1930 [5] – has been 
increasingly recognised as a distinct entity from that of lung SCC with a different 
biological behaviour and prognosis. More specifically, the SCC of the gastrointestinal 
tract is a rare entity and typically presents at advanced stage. We present this case for its 
rarity and to share our positive experience in terms of outcome from treatment. Most 
available literature on this condition exists in the form of case reports and retrospective 
studies and therefore, much remains to be uncovered about the natural history and the 
optimal treatment of the disease. 
The neuroendocrine differentiation of the tumour is usually demonstrated by 
immunochemical methods or electron microscopy. Positive immunoreactivity to at least 
2 neuroendocrine markers is required [6], which in our case were CD56 and 
chromogranin. The disease staging is evaluated in a similar fashion to the one used for 
SCC of the lung and is essentially divided into 2 major groups: limited disease or Case Rep Oncol 2011;4:475–480 
DOI: 10.1159/000332760 
Published online: 
September 21, 2011
© 2011 S. Karger AG, Basel
ISSN 1662–6575 
www.karger.com/cro   
 
 
 
477
extensive disease, purely based on the ability to cover the whole disease in an acceptable 
radiotherapy portal. 
In a retrospective study of 64 cases in the United States [1] (2004), the leading location 
for EPSCC was colon and rectum with a median age at presentation of 55 years and slight 
male predominance. The median survival ranged from 6–12 months for treated patients 
and in weeks for untreated patients. Another retrospective study of 24 patients [7] from 
Korea reported a median overall survival of 15.3 months and a 3-year survival rate of 
30%. 
The treatment approach is extrapolated from experience with SCLC. Studies up to date 
have invariably shown dismal prognostic outcomes for EPSCC as the disease is 
universally fatal and the 5-year survival rate as low as 13%. The options for extensive 
disease are to offer systemic chemotherapy or best supportive care. The approach for 
limited disease is not as clear. Some suggest only local treatments using surgery or 
radiotherapy and others suggest multimodality approach or chemotherapy alone [8]. One 
study on 54 patients with limited disease EPSCC reported an unfavourable outcome with 
local therapy alone (median disease-free survival of 5–6 months). In another evaluation of 
81 patients with EPSCC, the majority with limited disease, the combination of 
chemotherapy and radiation therapy was found to be as effective as surgery [9]. The 
majority favour a combined modality approach using sequential or concurrent chemo-
radiotherapy [7]. 
Our treatment approach was unique, as we employed sequential chemoradiation 
followed by maintenance chemotherapy resulting in a long-term disease-free survival. We 
know from SCLC experience that these patients do respond to combined modality 
treatment initially but usually present with relapse fairly quickly. In the above study of 81 
patients, the median time to relapse following initial response in patients with limited 
disease was 11.5 months [9]. Another study of 16 patients with reported rectal SCC had 
only 3 long-term survivors who were alive 5 years after the time of diagnosis and as 
expected, all of them had limited disease [10]. 
With our limited experience, we recommend aggressive multimodality treatment of 
limited-stage extrapulmonary SCLC and consideration for maintenance chemotherapy 
after initial good response in young and fit patients to transform initial response into a 
long-term disease control and possibly cure. 
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Fig. 1. CT July 2005. Rectal mass with lymph node involvement. 
 
 
 
Fig. 2. The tumour with large closely packed pleomorphic nuclei and smooth hyperchromatic nuclear 
chromatin. A few cells show nuclear moulding, which is suggestive of neuroendocrine differentiation. 
As well as areas of necrosis, there are also many apoptotic cells. This, together with the high rate of 
mitosis, reflects the high grade nature of the tumour. 
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Fig. 3. Membrane staining with CD56 (NCAM – Neural Cell Adhesion Molecule), confirming the 
neuroendocrine nature of the tumour. 
 
 
 
Fig. 4. CT July 2006 – post-chemoradiotherapy. Residual perirectal soft tissue at 10 o’clock at the level 
of seminal vesicles, extending to the mesorectal membrane which remained the same in subsequent 
scans and inactive in PET CT. 
 
 
 
 
 Case Rep Oncol 2011;4:475–480 
DOI: 10.1159/000332760 
Published online: 
September 21, 2011
© 2011 S. Karger AG, Basel
ISSN 1662–6575 
www.karger.com/cro   
 
 
 
480
References 
1  Brenner B, Shah MA, Gonen M, Klimstra DS, Shia J, Kelsen DP: Small-cell carcinoma of the gastrointestinal 
tract: a retrospective study of 64 cases. Br J Cancer 2004;90:1720–1726. 
2  Pearse AG: The diffuse neuroendocrine system and the APUN concept: related ‘endocrine’ peptides in brain, 
intestine, pituitary and anuran cutaneous glands. Med Biol 1077;55:115–125. 
3  Clery AP, Docktery MD, Waugh JM: Small cell carcinoma of the colon and rectum: a clinopathologic study. 
Arch Surg 1961;83:164–171. 
4  Saclarides TJ, Szeluga D, Staren ED: Neuroendocrine cancers of the colon and rectum. Results of a ten-year 
experience. Dis Colon Rectum 1994;37:635–642. 
5  Duguid J, Kennedy A: Oat cell tumors of mediastinal glands. J Pathol Bacteriol 1930;33:93–99. 
6  Cebrian J, Larach SW, Ferrara A, Williamson PR, Trevisani MF, Lugan HJ, Kassir A: Small cell carcinoma of 
the rectum: report of two cases. Dis Colon Rectum 1999;42:274–277. 
7  Kim JH, Lee S-H, Park J, Kim HY, Lee S, Nam EM, Park J-O, Kim K, Jung CW, Im Y-H, Kang WK, Lee MH, 
Park K: Extrapulmonary Small-cell carcinoma: a single-institution experience. Jpn J Clin Oncol 2004;34:250–
254. 
8  Arai K, Matsuda M: Gastric small cell carcinoma in Japan, a case report and review of the literature. Am J Clin 
Oncol 1998;21:458–461. 
9  Galanis E, Frytak S, Lloyd RV: Extrapulmonary small cell carcinoma. Cancer 1997;79:1729–1736. 
10  Yasui O, Tsukamoto F, Kudo K: Small cell undifferentiated carcinoma of the ascending colon with rapid 
enlargement after resection: report of a case and review of the literature. Tohoku J Exp Med 2006;209:361–367. 